Cell News and Research

RSS

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

Scientists find evidence of a ‘different’ flu virus in bats

They were surprised to find genetic fragments of a flu virus in bats. So far, scientists haven't been able to grow it, and it's not clear if — or how well — it spreads. Flu bugs are common in humans, birds and pigs and have even been seen in dogs, horses, seals and whales, among others. About five years ago, Russian virologists claimed finding flu in bats, but they never offered evidence.

28 Feb 2012

CNRS/Inserm researchers discover new family of anti-cancer compounds

A French-Italian team headed by researchers from CNRS and Inserm has discovered a new family of compounds that could make it possible to treat numerous cancers, particularly brain tumors and skin cancers.

28 Feb 2012

Scientists demonstrate how immortal flatworm overcomes aging process

Researchers from The University of Nottingham have demonstrated how a species of flatworm overcomes the ageing process to be potentially immortal.

28 Feb 2012

Largest study to date to observe dynamic social scenes in children with ASD

In a study published in the March 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry, Katherine Rice and colleagues, from the Marcus Autism Center, Children's Healthcare of Atlanta, and Emory University School of Medicine, used eye-tracking technology to measure the relationship between cognitive and social disability in children with autism spectrum disorders (ASD) and the ability of children with ASD to pay attention to social interactions.

28 Feb 2012

Aurora-A protein blocks proper functioning of tumor-suppressor p73

A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.

28 Feb 2012

Study identifies new processes that lead to development of novel cell implicated in allergies

A collaboration between scientists in Trinity College Dublin and the United Kingdom has identified new processes that lead to the development of a novel cell implicated in allergies. The discovery has the potential for new strategies to treat asthma and other allergic diseases.

28 Feb 2012

Octapharma submits octaplasLG BLA with FDA to treat TTP

Octapharma USA has submitted its Biological License Application (BLA) for octaplasLG to the U.S. Food and Drug Administration (FDA) with the goal of expanding its U.S. product portfolio by the fourth quarter of 2012.

28 Feb 2012

Chemically altered osteoporosis drug may fight malaria

A chemically altered osteoporosis drug may be useful in fighting malaria, researchers report in a new study. Unlike similar compounds tested against other parasitic protozoa, the drug readily crosses into the red blood cells of malaria-infected mice and kills the malaria parasite. The drug works at very low concentrations with no observed toxicity to the mouse.

27 Feb 2012

New RNA interference method holds promise for cancer, other diseases

For the past decade, scientists have been pursuing cancer treatments based on RNA interference - a phenomenon that offers a way to shut off malfunctioning genes with short snippets of RNA. However, one huge challenge remains: finding a way to efficiently deliver the RNA.

27 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Hand rejuvenation therapy effective for reducing damage

We greet each other with our hands, whether with a handshake or a wave. We absentmindedly show off our hands when we reach for something, point somewhere, or just scratch our heads. Our hands are almost always visible and unprotected from the elements.

27 Feb 2012

Dendreon 2011 product revenue increases to $213.5M

Dendreon Corporation today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

27 Feb 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012

EMA acceptance of peginesatide MAA triggers $5M milestone payment to Affymax

Affymax, Inc. today announced that it will receive a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize peginesatide.

27 Feb 2012

ATI commences European trial of neurostimulation system for migraine

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable stimulator for severe headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine.

27 Feb 2012